<DOC>
	<DOCNO>NCT00602771</DOCNO>
	<brief_summary>This randomized phase II trial study side effect well give tipifarnib together etoposide work treat old patient newly diagnose , previously untreated acute myeloid leukemia . Tipifarnib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , etoposide , work different way stop growth cancer cell , either kill cell stop divide . Giving tipifarnib together etoposide may kill cancer cell .</brief_summary>
	<brief_title>Tipifarnib Etoposide Treating Older Patients With Newly Diagnosed , Previously Untreated Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . To compare efficacy toxicity two schedule tipifarnib plus etoposide induction therapy old patient newly diagnose , previously untreated acute myeloid leukemia . II . To study mechanism leukemia cell resistance tipifarnib combination etoposide . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . ARM I : Patients receive 600 mg oral tipifarnib twice daily day 1-14 100 mg oral etoposide daily day 1-3 8-10 . ARM II : Patients receive 400 mg oral tipifarnib twice daily day 1-14 200 mg oral etoposide daily day 1-3 8-10 . ( closed accrual November 2008 ) Treatment arm repeat every 28 day absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day every 90 day thereafter .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>Criteria : Pathologically confirm newly diagnose acute myeloid leukemia ( AML ) Subtypes M0 , M1 , M2 , M47 disease No newly diagnose acute promyelocytic leukemia ( M3 ) Any follow disease : De novo disease Secondary AML Myelodysplasia ( MDS ) relate AML ( MDS/AML ) Treatmentrelated AML Previously untreated disease Patients receive prior hydroxyurea alone noncytotoxic therapy MDS ( e.g. , thalidomide , interferon , cytokine , 5azacytidine , revlimid ) eligible study Must consider ineligible traditional antileukemia chemotherapy No hyperleukocytosis â‰¥ 30,000 blasts/uL rapidly rise blast count project doubling time = &lt; 2 day Patients may receive hydroxyurea low blast count &lt; 30,000 blasts/uL 24 hour begin tipifarnib etoposide No active CNS leukemia No prior tipifarnib etoposide No concurrent radiotherapy , immunotherapy , chemotherapy No concurrent enzymeinducing anticonvulsant ( e.g. , phenytoin , fosphenytoin , phenobarbital , primidone , carbamazepine , oxcarbazepine ) Patients may change nonenzymeinducing anticonvulsant stabilize start study treatment ECOG performance status 02 Serum creatinine = &lt; 2.0 mg/dL SGOT SGPT = &lt; 3 time upper limit normal Bilirubin = &lt; 2 mg/dL Active , uncontrolled infection Patients infection active treatment control antimicrobial eligible Presence lifethreatening illnesses Patients mental deficit and/or psychiatric history preclude give informed consent follow protocol Allergies imidazole ( e.g. , clotrimazole , ketoconazole , miconazole , econazole )</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>